Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help? | Zendy

Ryan L. Crass | Zendy; Manjunath P. Pai | Zendy; Thomas P. Lodise | Zendy

Open Access

Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?

Author(s) -

Ryan L. Crass,

Manjunath P. Pai,

Thomas P. Lodise

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky388

Subject(s) - tobramycin , piperacillin , piperacillin/tazobactam , medicine , aminoglycoside , tazobactam , cystic fibrosis , population , pharmacokinetics , antibacterial agent , surgery , urology , antibiotics , gentamicin , microbiology and biotechnology , biology , pseudomonas aeruginosa , genetics , environmental health , bacteria

Empirical models to predict β-lactam pharmacokinetics (PK) using information from routine aminoglycoside therapeutic drug monitoring (TDM) have been proposed for critically ill patients; however, no such models exist for patients with cystic fibrosis (CF).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research